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Objectives The purposes of this study were to investigate whether, in patients with ST-segment elevation myocardial infarc-
tion (STEMI) and multivessel disease (MVD), percutaneous coronary intervention (PCI) should be confined to the
culprit or also nonculprit vessels and, when performing PCI for nonculprit vessels, whether it should take place
during primary PCI or staged procedures.
Background A significant percentage of STEMI patients have MVD. However, the best PCI strategy for nonculprit vessel le-
sions is unknown.
Methods Pairwise and network meta-analyses were performed on 3 PCI strategies for MVD in STEMI patients: 1) culprit
vessel only PCI strategy (culprit PCI), defined as PCI confined to culprit vessel lesions only; 2) multivessel PCI
strategy (MV-PCI), defined as PCI of culprit vessel as well as 1 nonculprit vessel lesions; and 3) staged PCI
strategy (staged PCI), defined as PCI confined to culprit vessel, after which 1 nonculprit vessel lesions are
treated during staged procedures. Prospective and retrospective studies were included when research subjects
were patients with STEMI and MVD undergoing PCI. The primary endpoint was short-term mortality.
Results Four prospective and 14 retrospective studies involving 40,280 patients were included. Pairwise meta-analyses
demonstrated that staged PCI was associated with lower short- and long-term mortality as compared with culprit
PCI and MV-PCI and that MV-PCI was associated with highest mortality rates at both short- and long-term follow-
up. In network analyses, staged PCI was also consistently associated with lower mortality.
Conclusions This meta-analysis supports current guidelines discouraging performance of multivessel primary PCI for STEMI.
When significant nonculprit vessel lesions are suitable for PCI, they should only be treated during staged
procedures. (J Am Coll Cardiol 2011;58:692–703) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.046The primary objective of percutaneous coronary interven-
tion (PCI) in patients with ST-segment elevation myocar-
dial infarction (STEMI) is to restore epicardial flow and
myocardial perfusion in the culprit vessel. However, the
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2011, accepted March 1, 2011.pathophysiological process of myocardial infarction is not
limited to the culprit vessel (1). It is estimated that 40% to
65% of the patients presenting with STEMI have multivessel
disease (MVD), which has been associated with worse clinical
outcome as compared with single-vessel disease (2). Patients
with MVD have in addition to the culprit lesion, 1 or more
significant lesions in nonculprit vessels. When nonculprit vessel
See page 712
lesions are suitable for PCI and coronary artery bypass graft
surgery (CABG) is not preferred, they can be treated according
to 3 different strategies. After having treated the culprit vessel,
the operator can choose to treat nonculprit vessel lesions
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during staged PCI procedures.
Although current international guidelines do not recom-
mend performance of PCI for nonculprit vessels in patients
unless there is hemodynamic instability (Class III, Level of
Evidence: C) (3,4), no large randomized controlled trials have
been performed or planned comparing these 3 strategies. There-
fore, it remains uncertain whether treatment of nonculprit
vessels is required and when it should be performed in patients
presenting with STEMI.
Recently several small prospective and large retrospective
studies have been published comparing these strategies. To
evaluate the composite data, we performed a systematic
review of all published data to summarize current evidence
for these 3 current PCI strategies for MVD in STEMI
patients. Pairwise meta-analyses were performed to com-
pare these PCI strategies, and an additional network anal-
ysis was carried out to investigate the robustness of the
Main Characteristics of Included StudiesTable 1 Main Characteristics of Included Studies
Primary Author,
Year Published
(Ref. #) Setting
Symptom–Time,
h*
PCI Strategies
Culprit
PCI MV-PCI
Stag
PC
Prospective studies
Di Mario, 2004 (5) Multicenter 12 17 52 —
Ochala, 2004 (6) Single-center 12 — 48 44
Politi, 2010 (7) Single-center 24 84 65 65
Khattab, 2008 (8) Single-center 12 45 28 —
Retrospective studies
Cavender, 2009 (9) Multicenter All 25,802 3134 —
Corpus, 2004 (10) Single-center 12 354 26 126
Dziewierz, 2010 (11) Multicenter 707 70 —
Han, 2008 (12) Single-center 149 — 93
Hannan, 2010 (13)‡ Multicenter 24 3,262 503 259
Kong, 2006 (14) Multicenter 24 1,350 632 —
Mohamad, 2010
(15)
Single-center 12 30 7 12
Poyen, 2003 (16) Single-center 12 81 86 —
Qarawani, 2008 (17) Single-center 12 25 95 —
Rigattieri, 2007 (18) Single-center 12 46 — 64
Roe, 2001 (19) Multicenter 79 79 —
van der Schaaf,
2010 (20)
Single-center 6 124 37 —
Toma, 2010 (21) Multicenter 6 1,984 217 —
Varani, 2008 (22) Single-center 24 156 147 96
*Time between symptom onset and hospital admission. †Cardiogenic shock defined as reported
CABG  coronary artery bypass graft surgery; CTO  chronic total occlusion; FU  follow-up; LM 
percutaneous coronary intervention.pairwise meta-analyses, to com-
bine both direct and indirect ev-
idence, and to rank these 3 PCI
strategies.
Methods
Definitions of the 3 PCI strat-
egies. The 3 PCI strategies for
STEMI patients with MVD
were defined as follows: The cul-
prit vessel only PCI (culprit PCI)
strategy was defined as PCI con-
fined to culprit vessel lesions
only. The multivessel PCI (MV-PCI) strategy was defined
as PCI in which lesions in the culprit vessel as well as 1
nonculprit vessel lesion were treated. All interventions
should have had taken place within the same procedure.
ups, n
Exclusion Criteria
Maximum
Follow-Up
Timing of
Staged PCI
— LM, shock,† CTO, lesions located in graft or previously
treated with PCI, thrombolytic therapy before PCI.
No culprit vessel lesion suitable for stenting; diffuse
calcification, severe tortuosity, risk of side branch
occlusion.
1 yr
7.3 12.8 days LM, shock,† previous CABG, severe valvular disease,
no PCI possible in nonculprit vessel (diffuse 4 cm,
diameter 2.5 mm, severe tortuosity, lesion within
orifices of large side branch), renal insufficiency or
1 kidney, contraindications for antiplatelet therapy,
pregnancy
6 months
6.8 12.9 days LM, shock,† previous CABG, severe valvular disease,
unsuccessful culprit vessel PCI
2.5 1.4 yrs
— LM, CTO, previous MI, nonculprit vessel diameter
2.5 mm, extensive calcification
1 yr
— LM, thrombolytic therapy before PCI, staged PCI In-hospital
-hospital LM, PCI in vein graft or for acute occlusion after
coronary angioplasty, staged PCI after hospital
discharge
1 yr
— Previous CABG 1 yr
–15 days LM, shock,† pulmonary edema, cardiac rupture 1 yr
-hospital LM, shock,† previous open heart surgery, thrombolytic
therapy before PCI, missing ejection fraction
3.5 yrs
— LM, shock or hemodynamic instability,
cardiopulmonary resuscitation, previous
MI/PCI/CABG
In hospital
/A Unable to undergo CABG 3 h hospital presentation 1 yr
— Shock† 2.5 yrs
— LM, shock† 1 yr
-hospital LM, shock,† previous CABG, severe valvular disease 1 yr
— LM, PCI of side branch
— Patients without shock† 1 yr
— LM, second PCI in culprit vessel, rescue PCI, isolated
inferior MI, serious comorbidity, pregnancy or
breastfeeding
3 months
-hospital PCI for acute occlusion after coronary angioplasty 1.7 1.0 yr
tudies. ‡Different matched populations are used in the pairwise comparisons.
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
MV  multivessel
MVD  multivessel disease
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionSubgro
ed
I
2
5
In
7
In
N
In
In
in the s
left main stenosis; MI  myocardial infarction; MV  multivessel; N/A  not available; PCI 
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culprit vessel lesions only, after which 1 lesions in non-
culprit vessel were treated during planned secondary proce-
dures. The timing of staged PCI procedures was defined as
reported in each study (Table 1) (5–22).
In studies investigating solely culprit PCI versus MV-
PCI, the primary focus was often only on the strategy
during the initial procedure and no details were given about
whether planned staged procedures were allowed in patients
treated according to the culprit PCI strategy. In these cases,
studies were included but the applied definitions were
extracted and used as a quality indicator. Authors were
contacted in case of unclear definitions.
Study selection. MEDLINE and Cochrane Controlled
Trials Register searches were performed to identify relevant
articles published between 1985 and August 2010. The
following key words and medical subject headings (MeSH)
terms were used: “percutaneous coronary intervention,”
“angioplasty,” “stent,” “balloon,” “dilatat*,” “multivessel,”
“multi-vessel,” “staged,” “culprit,” “infarct-related,” “myo-
card* infarct*,” “myocardial infarction[MeSH],” “angio-
plasty, transluminal, percutaneous coronary[MeSH],”
“stents[MeSH],” and “balloon dilatation[MeSH].” Refer-
ence lists of selected articles were reviewed for other
potentially relevant articles. Two independent reviewers
(P.V. and K.M.) performed the study selection.
Both prospective and retrospective studies were consid-
ered for inclusion. Studies were selected if the study (sub-
)group consisted of STEMI patients with MVD who
underwent acute PCI. At least survival data had to be
available and stratified to at least 2 of the 3 PCI strategies
Figure 1 Flow Design
Flow diagram of study inclusion and exclusion. PCI  percutaneous coronary interfor MVD. Studies investigating the impact of completeness
of revascularization (so comparing complete versus incom-
plete revascularization) or surgical revascularization for
MVD were excluded. In addition, studies investigating PCI
in elective patients and acute coronary syndromes with
MVD were also excluded. No studies were excluded based
on baseline or angiographic criteria.
Data extraction. Data extraction was performed indepen-
dently by 2 researchers (P.V. and K.M.). Information was
collected with regard to study design, quality indicators,
baseline clinical characteristics, procedural details, clinical
outcomes, and safety outcomes. Authors were contacted in
case of incomplete or unclear data.
Endpoints. The primary endpoint was short-term (in-
hospital/30 days) mortality. Secondary endpoints were long-
term mortality, reinfarction, any revascularization, major
bleeding, and stroke. Unless otherwise specified, mortality
included both cardiac and noncardiac death. Stroke included
both ischemic and hemorrhagic stroke. Major bleeding was
defined as the need for blood transfusion during hospitaliza-
tion. Reinfarction as well as MVD and cardiogenic shock were
defined as reported in the studies.
Statistical methods. Absolute numbers and percentages of
the endpoints were calculated for each study separately and
all studies combined. For the direct pairwise meta-analyses,
pooled estimates and 95% confidence intervals (CIs) were
calculated assuming a random-effects model with inverse-
variance weighting using the DerSimonian and Laird
method to account for heterogeneity. The following pairs
were analyzed: culprit PCI versus MV-PCI, culprit PCI
versus staged PCI, and MV-PCI versus staged PCI. Het-
; STEMI  ST-segment elevation myocardial infarction.vention
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August 9, 2011:692–703 Culprit Versus Multivessel Versus Staged PCI in STEMIerogeneity across studies was tested by the Cochran’s Q
statistic and the I2 statistic. Funnel plots were used to assess
otential publication bias. Subgroups were made based on
esign (prospective and retrospective studies) and shown for
ach comparison and endpoint. A subanalysis was per-
ormed on culprit PCI versus MV-PCI in cardiogenic shock
atients. Pairwise analyses were performed using Review
anager (version 5.0.24).
A network analysis (23–25) was carried out to investigate
he robustness of our findings and to combine both direct
nd indirect evidence about the 3 PCI strategies. The
nalysis was carried out using 3 types of random effects
odels: a consistency model and an inconsistency model
25), and a node-splitting model (26). Vague priors were
pecified in all of the models: N(0, 1,000) for effect
arameters and U(0, 4) for variance parameters. As the
vidence structure is a triangle, there is only 1 inconsistency
actor w in the inconsistency model. In the node-splitting
odel, we split the node dm,s (MV-PCI vs. staged PCI) into
direct evidence:
d
Dir
m, s
Quality of Prospective StudiesTable 2 Quality of Prospective Studies
Primary Author,
Year Published
(Ref. #) RCT
Power
Calculation
Blinded
Assessment of
Angiographic Data
Ad
of
Di Mario, 2004 (5) Yes Yes Yes
Ochala, 2004 (6) Yes No Yes
Politi, 2010 (7) Yes Yes No
Khattab, 2008 (8) No No No
ITT  intention-to-treat; RCT  randomized clinical trial; other abbreviations as in Table 1.
Quality of Retrospective StudiesTable 3 Quality of Retrospective Studies
Primary Author,
Year Published
(Ref. #) Control for Confounders
Blinded Ass
of Angiogra
Cavender, 2009 (9)  (subanalysis of prospective registry) —
Corpus, 2004 (10) — —
Dziewierz, 2010 (11)  (subanalysis of prospective registry) —
Han, 2008 (12) — —
Hannan, 2010 (13)  (subanalysis of prospective registry) —
Kong, 2006 (14)  (subanalysis of prospective registry) —
Mohamad, 2010 (15) — —
Poyen, 2003 (16) — —
Qarawani, 2008 (17) — —
Rigattieri, 2007 (18) — —
Roe, 2001 (19) — —
van der Schaaf, 2010
(20)
— —
Toma, 2010 (21)  (subanalysis of prospective study) —
Varani, 2008 (22)  (subanalysis of prospective registry) —  issue possibly source of bias;   issue likely to be source of bias; other abbreviations as in Tableand indirect evidence:
d
Ind
m, s
Inconsistency was assessed by: 1) comparing deviance infor-
mation criterion model fit across the 3 models (25); 2)
testing w  0 (25); and 3) testing
d
Dir
m, s
 d
Ind
m, s
26
Both hypothesis tests were performed using the Bayesian
p value (26). All models were computed using Markov chain
Monte Carlo simulation in JAGS (27) and R (28) using 3
chains with over-dispersed initial values. The models were
run for 300,000 iterations, after which convergence was
assessed using the Brooks-Gelman-Rubin diagnostic (29).
fter this, all inference was based on a further 100,000
terations.
All p values were 2-tailed, with statistical significance set
t 0.05. This meta-analysis was performed in compliance
ith published recommendations for meta-analyses (30).
ion
se ITT
Analysis
Definition of Culprit PCI
Regarding Staged
Procedures
Completeness of
Survival Data
N/A Staged procedures allowed 100%
N/A No staged procedures allowed 100%
Yes No staged procedures allowed Mean follow-up used
N/A Staged procedures allowed
1–3 months after primary PCI
93%
nt
ta
Preferred PCI
Strategy
Definition of Culprit PCI
Regarding Staged
Procedures
Completeness
of Survival Data
N/A No staged procedures allowed N/A
Operator decision No staged procedures allowed 100%
N/A No staged procedures allowed 100%
Operator decision No staged procedures allowed 99.5%
N/A No staged procedures allowed N/A
Operator decision N/A N/A
N/A No staged procedures allowed N/A
Multivessel PCI Staged procedures allowed 98.8%
Operator decision Staged procedures allowed N/A
Operator decision No staged procedures allowed 95.5%
Operator decision Staged procedures allowed 100%
N/A N/A N/A
N/A N/A 99.7%
Operator decision No staged procedures allowed 95.0%judicat
Adver
Events
No
No
No
Noessme
phy Da1.
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Culprit Versus Multivessel Versus Staged PCI in STEMI August 9, 2011:692–703Two researchers (P.V. and G.V.) had full access to and take
full responsibility for the integrity of the data.
Results
Eighteen studies, involving 40,280 patients, met our inclu-
sion criteria (Fig. 1) (5–22). All included STEMI patients
Figure 2 Evidence for Primary Endpoint Short-Term Mortality
(A) Evidence for primary endpoint short-term mortality in pairwise meta-analyses. (
PCI  percutaneous coronary intervention.
Baseline Characteristics of Included StudiesTable 4 Baseline Characteristics of Included Studies
Primary Author,
Year Published
(Ref. #)
Age, Mean, yrs Male, %
Culprit
PCI MV-PCI
Staged
PCI
Culprit
PCI MV-PCI
Prospective studies
Di Mario, 2004 (5) 65.3 53.5 — 84.6 88.2
Ochala, 2004 (6) — 65.0 67.0 — 72.9
Politi, 2010 (7) 66.5 64.5 64.1 76.2 76.9
Khattab, 2008 (8) 65.0 69.0 — 77.8 75.0
Retrospective studies
Cavender, 2009 (9) 62.0* 60.0* — 72.1 71.5
Corpus, 2004 (10) 63.0 N/A N/A 69.2 N/A
Dziewierz, 2010 (11) N/A N/A — N/A N/A
Han, 2008 (12) 61.0 — 60.0 79.9 —
Hannan, 2010 (13)† N/A N/A N/A 78.7 75.0
Kong, 2006 (14) 62.0 60.0 — 72.1 77.2
Mohamad, 2010 (15) N/A N/A N/A N/A N/A
Poyen, 2003 (16) N/A N/A — N/A N/A
Qarawani, 2008 (17) 67.0 66.0 — 64.0 65.3
Rigattieri, 2007 (18) 68.0 — 64.8 69.6 —
Roe, 2001 (19) 63.0* 64.0* — 65.8 77.2
van der Schaaf, 2010 (20) N/A N/A — N/A N/A
Toma, 2010 (21) 64.0* 64.0* — 79.4 77.4
Varani, 2008 (22) 79.8 68.7 67.1 75.0 67.4
Summary of baseline mean/percentage
for studies included in each
pairwise analysis
Culprit vs. MV-PCI 62.3 60.7 — 72.7 73.0
Culprit vs. staged PCI 69.5 — 63.9 77.6 —
MV vs. staged PCI — 67.0 66.1 — 73.6*Median instead of mean. †Different matched populations are used in the pairwise comparisons.
Excl  excluded from analysis; other abbreviations as in Table 1.with MVD who underwent PCI. Of the 18 included
studies, 4 studies were prospective studies and 14 were
retrospective studies (Table 1). Two retrospective studies
compared PCI strategies between matched populations
(13,19). Five studies compared all 3 PCI strategies
(7,10,13,15,22), 10 studies compared culprit PCI versus
dence for primary endpoint short-term mortality in network meta-analysis.
Diabetes, % 3-Vessel Disease, % Shock, %
ed Culprit
PCI MV-PCI
Staged
PCI
Culprit
PCI MV-PCI
Staged
PCI
Culprit
PCI MV-PCI
Staged
PCI
41.2 11.5 — 47.1 30.8 — Excl Excl —
— 31.3 34.1 — N/A N/A — Excl Excl
23.8 13.8 18.5 25.0 29.2 44.6 Excl Excl Excl
15.6 7.1 — 48.9 60.7 — 4.4 3.6 —
23.4 24.7 — N/A N/A — 10.3 13.8 —
17.0 N/A N/A N/A N/A N/A 3.4 N/A N/A
N/A N/A — 36.5 31.4 — N/A N/A —
33.6 — 33.3 16.1 — 18.3 Excl — Excl
N/A N/A N/A 26.4 25.7 42.1 Excl Excl Excl
20.5 16.8 — N/A N/A — Excl Excl —
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A — 40.7 14.0 — Excl Excl v
16.0 12.6 — 44.0 43.2 — Excl Excl —
32.6 — 15.6 47.8 — 29.7 Excl — Excl
29.1 37.2 — N/A N/A — 27.8 27.8 —
N/A N/A — N/A N/A — 100.0 100.0 —
20.0 11.5 — 31.8 25.8 — 1.2 1.8 —
N/A N/A N/A 34.0 35.4 46.9 6.4 15.0 4.2
23.0 22.4 — 32.5 28.8 — 9.4 10.2 —
30.5 — 23.9 27.0 — 38.0 2.7 — 2.1
— 21.2 24.8 — 28.0 43.6 — 2.9 0.9B) EviStag
PCI
—
75.0
80.0
—
—
N/A
—
78.5
84.2
—
N/A
—
—
79.7
—
—
—
67.7
—
79.6
79.3
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August 9, 2011:692–703 Culprit Versus Multivessel Versus Staged PCI in STEMIMV-PCI (5,8,9,11,14,16,17,19 –21), 2 studies compared
culprit PCI versus staged PCI (12,18), and 1 study
compared MV-PCI versus staged PCI (6).
In the majority of the studies MVD was defined as a
significant stenosis in 1 major epicardial vessel or side
ranch, but in 2 studies a left main stenosis was also defined
s 2-vessel disease (20,21). Significant was defined as70%
tenosis, except for 2 studies that used 50% (19,20).
The timing of staged procedures was in the majority of the
tudies during hospitalization or within 1 month after index
CI (Table 1). Details about the quality of included prospec-
ive and retrospective studies are given in Tables 2 and 3. Six of
4 retrospective studies were subanalyses of prospective regis-
ries. In addition, details are given regarding the studies in
hich planned staged procedures were allowed in patients
reated according to the culprit PCI strategy. Assessment of
unnel plots suggested no publication bias.
Figure 3 Culprit PCI Versus MV-PCI and Staged PCI Short-Term
(A) Results of pairwise and network meta-analyses of studies comparing culprit le
versus multivessel (MV) PCI for short-term mortality.Analyses were performed on short- and long-term
ortality. Available evidence for the primary endpoint of
hort-term mortality in pairwise and network compari-
ons is shown in Figure 2. A proper analysis on the
econdary endpoints of reinfarction, any revasculariza-
ion, major bleeding, and stroke was not possible because
ata were only available for a minority of the studies.
everal authors provided additional information and
utcome data (8,9,11,13,14,20 –21).
ate of the 3 PCI strategies across retrospective studies.
n retrospective cohort studies (total 37,436 patients)
9 –11,22) providing rates of all 3 PCI strategies for
VD in their populations, culprit PCI was always the
ost often performed PCI strategy (30,260 of 37,436
atients, 80.8%) as compared with MV-PCI (3,887 of
7,436 patients, 10.4%) and staged PCI (3,289 of 37,436
atients, 8.8%).
tality
ercutaneous coronary intervention (PCI)
Continued on the next pageMor
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summary of baseline variables for each included study group
are detailed in Table 4. In addition, summaries of baseline
mean/percentages are given for studies included in each
pairwise analysis. In studies comparing culprit PCI versus
MV-PCI, patients treated according to culprit PCI were
older (62.3 years vs. 60.7 years) and had higher rates of
3-vessel disease (32.5% vs. 28.8%). No differences were
observed regarding sex (male 72.7% vs. female 73.0%),
diabetes mellitus (23.0% vs. 22.4%), and cardiogenic shock
(9.4% vs. 10.2%).
The pairwise analyses. SHORT-TERM MORTALITY. Pooled
short-term outcome data are detailed in Figures 3A to 3C. The
staged PCI strategy was superior in both the comparison
with culprit PCI (odds ratio [OR]: 3.03, 95% CI: 1.41 to
6.51, p  0.005), and MV-PCI (OR: 5.31, 95% CI: 2.31
to 12.21, p  0.0001). In addition, mortality was lower in
patients treated according to the culprit PCI strategy as
compared with MV-PCI (OR: 0.66, 95% CI: 0.48 to
0.89, p  0.007). Only in the pairwise analysis of culprit
PCI versus MV-PCI, signs of heterogeneity were found
across the trials (I 2  47%).
Two studies investigated culprit PCI versus MV-PCI in
patients presenting in cardiogenic shock (20,26). A total of
3,248 patients was included, of which 470 (14.4%) were
Figure 3 Continued
(B) Results of pairwise and network meta-analyses of studies comparing culprit PCtreated according to the MV-PCI strategy. Short-term
mortality was in both studies lower among patients treated
according to the culprit PCI strategy (total effect OR: 0.68,
95% CI: 0.56 to 0.84, p  0.0003).
LONG-TERM MORTALITY. Pooled long-term outcome data
are detailed in Figures 4A to 4C. Also at long-term
follow-up, staged PCI was associated with significant lower
mortality rates as compared with culprit PCI and MV-PCI.
No significant heterogeneity was observed across trials.
The network analysis. All models had adequate conver-
gence. There was no significant inconsistency in either
short-term mortality (p  0.94 in the inconsistency model,
p  0.75 in the node-splitting model, and similar deviance
nformation criteria for all 3 models) or long-term mortality
p  0.90 in the inconsistency model, p  0.78 in the
ode-splitting model, and similar deviance information
riteria for all 3 models).
Posterior means and 95% credibility intervals for the relative
ffects (OR) are shown for each comparison and for both
hort-term and long-term mortality in Figures 3 and 4.
In addition, the rank-probability of the 3 PCI strategies
as investigated. This analysis demonstrated that for the
rimary endpoint short-term mortality, the staged PCI
trategy had a 0.9998 probability of being the best treatment
us staged PCI for short-term mortality. Continued on the next pageI vers
m
a
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August 9, 2011:692–703 Culprit Versus Multivessel Versus Staged PCI in STEMIas compared with culprit PCI (second rank probability of
0.94) and MV-PCI (third rank probability of 0.94). For
long-term mortality, the rank-probability analysis also dem-
onstrated that staged PCI had 0.995 probability of being the
best treatment as compared with culprit PCI (second rank
probability of 0.990) and MV-PCI (third rank probability
of 0.996).
Discussion
This meta-analysis supports current guidelines advising the
performance of primary PCI for STEMI confined to the
culprit vessel only. Multivessel PCI should be discouraged,
and significant nonculprit vessel lesions should only be
treated during planned staged procedures. Although con-
sidered safe, PCI remains associated with potential serious
procedural complications, such as restenosis, stent throm-
bosis, and contrast-induced nephropathy (3,4). Interna-
tional guidelines, therefore, recommend using PCI selec-
tively in cases in which the benefit of a revascularization
outweighs the risk of complications. For elective PCI,
extensive research has resulted in the consensus that it
should be performed selectively in significant coronary
lesions that cause myocardial ischemia (3,4). For lesions that
do not induce ischemia, the benefit of revascularization is
Figure 3 Continued
(C) Results of pairwise and network meta-analyses of studies comparing MV-PCI v
IV  inverse variance.less clear. For these patients, an initial conservative medical
strategy is likely to be as effective (3,4,31). However, in the
context of STEMI, it is less clear how significant lesions in
nonculprit vessels should be treated.
Current guidelines indicate that MV-PCI should not be
performed in hemodynamic stable STEMI patients (3,4).
Only for patients in cardiogenic shock, PCI maybe recom-
mended for all critically stenosed large epicardial coronary
arteries. However, no randomized data have been published
indicating that MV-PCI is beneficial for cardiogenic shock
patients. Because of limited evidence on this subject, different
opinions exist on the use of MV-PCI for STEMI across
centers and operators. That is illustrated by a recent analysis of
the National Cardiovascular Data Registry database, which
found incidences of MV-PCI ranging between 0% and 38% in
some participating centers (9). One potential source of this
variability may be the result of the operator considering that
there were multiple infarct-related artery lesions/arteries.
It has been hypothesized that for selected STEMI patients
(e.g., cardiogenic shock), PCI of the nonculprit vessel in the acute
phase is able to reduce (border zone) ischemia and improve
survival (32,33). In addition, when1 culprit lesion is suspected,
ultivessel PCI may also be beneficial (1). Multivessel PCI may
lso be more convenient for the patient, as no secondary proce-
staged PCI for short-term mortality. CI  confidence interval;ersus
700 Vlaar et al. JACC Vol. 58, No. 7, 2011
Culprit Versus Multivessel Versus Staged PCI in STEMI August 9, 2011:692–703dures are necessary. Further, there are logistic and economic
reasons to perform MV-PCI as it may limit staged procedures and
reduces length of hospital stays, and thereby medical costs.
However, the present meta-analysis found that MV-PCI during
the acute phase of STEMI was associated with higher mortality
rates as compared with culprit PCI or staged PCI. A small
subanalysis in cardiogenic shock patients also did not show any
mortality benefit of a MV-PCI strategy in these patients. A
recently published smaller pairwise meta-analysis on culprit PCI
versus MV-PCI also found no benefit of MV-PCI over culprit
PCI (34). However, it did not find MV-PCI to be associated with
increased long-term mortality. These inconsistent long-term re-
sults are likely explained by methodological and statistical differ-
ences between the 2 meta-analyses. Nevertheless, these data
indicate that the possible benefits of multivessel PCI do not
outweigh the adverse effects associated with this aggressive strat-
egy. These adverse effects are likely to be explained by the
following factors.
First, the enhanced thrombotic and inflammatory envi-
Figure 4 Culprit PCI Versus MV-PCI and Staged PCI for Long-Te
(A) Results of pairwise and network meta-analyses of studies comparing culprit leronment of STEMI contributes to a higher risk of proce-dural complications as compared with elective procedures
(35–39). Factors that increase risk are related to the com-
plexity and duration of the procedure, which is the case with
multivessel PCI for STEMI. Although a secondary staged
PCI may also relate to an increased risk of complications,
our results indicate that the risk associated with a secondary
staged PCI is lower than that with an acute PCI.
Second, when performing multivessel PCI of signifi-
cant nonculprit vessel, the PCI will be performed without
objective evidence for the presence of myocardial isch-
emia. As the actual significance of a stenosis may be
difficult to determine due to several factors in the acute
phase of STEMI (39,40), routine multivessel PCI of
nonculprit vessel lesions can result in PCI of clinical
irrelevant lesions. The benefit of not treating nonculprit
vessel lesions during the acute phase is that coronary
angiograms can be discussed within a joint heart team to
determine the best strategy for each individual patient
(3,4). In the case of intermediate lesions, additional
ortality
CI versus MV PCI for long-term mortality. Continued on the next pagerm M
sion Pnoninvasive ischemia tests and fractional flow reserve
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form additional revascularizations (3,4,41).
Study limitations. Because of limited randomized data,
this meta-analysis included both prospective and retrospec-
tive studies. As a consequence, the majority of the included
studies were retrospective cohort analyses. The inclusion of
studies with different designs and retrospective studies is
likely to have induced heterogeneity in the results, as
illustrated by the differences found between prospective and
retrospective studies. Further, in most studies, the operator’s
intent to perform 1 of the 3 PCI strategies was not
prospectively registered and may be influenced by important
patient characteristics for which we were not able to adjust.
The results and conclusions should be interpreted with these
limitations in mind. However, we have carried out a network
analyses to assess the robustness of our findings and combining
direct and indirect evidence about the 3 strategies. In this
analysis, staged PCI was also consistently associated with
significant lower mortality rates at both short-term and long-
term follow-up as compared with culprit PCI and MV-PCI.
Only the comparison between culprit PCI and MV-PCI for
short-term mortality lost significance. Additional analyses
demonstrated that was not due to the indirect comparisons, but
Figure 4 Continued
(B) Results of pairwise and network meta-analyses of studies comparing culprit PCto the direct comparison in the network analysis being per-formed according to the Bayesian instead of the DerSimonian
and Laird method.
Furthermore, the analyses between culprit PCI and MV-
PCI in the included studies were primarily focused on the
index PCI procedure. Therefore, in some studies, staged
PCI was allowed in the culprit PCI group. That may have
influenced the results, however, only in the culprit PCI
versus MV-PCI and not the other pairwise comparisons. In
addition, when excluding studies that allowed staged PCI
procedures or did not provide information on this, a
significant short-term mortality benefit of culprit PCI over
MV-PCI was still observed. Finally, the role of timing of
staged PCI procedures, CABG, and use of noninvasive
ischemia testing in the management of MVD were neither
investigated nor discussed in the majority of the studies.
Conclusions
This meta-analysis supports current guidelines discouraging
performance of multivessel primary PCI for STEMI. When
significant nonculprit vessel lesions are suitable for PCI,
they should only be treated during staged procedures. More
prospective research should be performed to investigate
us staged PCI for long-term mortality. Continued on the next pageI verswhich strategy is superior, in both hemodynamic stable and
v1
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Culprit Versus Multivessel Versus Staged PCI in STEMI August 9, 2011:692–703unstable STEMI patients (CABG vs. culprit PCI vs. staged
PCI vs. MV-PCI). We, therefore, propose a prospective
international registry to investigate these strategies. To
facilitate intention-to-treat comparisons between the differ-
ent strategies for multivessel PCI, this registry should focus
on registering the operator’s intent to perform 1 of the
strategies at the time of the initial PCI.
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